A 45-year-old woman with chronic hepatitis C was treated with peginterferon alpha-2b in
combination with ribavirin, which activated psoriasis. In the patient, psoriasis reoccurred …

A 56-year-old man with chronic hepatitis C was treated with pegylated interferon alfa-2a in
combination with ribavirin. However, psoriatic lesions appeared and worsened dramatically …

This paper describes the clinical course of a patient with chronic hepatitis C, genotype 2a/2c,
previously treated with Interferon α2b and subsequently with Lymphoblastoid Interferon …

A 47 year old man with chronic hepatitis C was treated with interferon alfa, 3 million units
three times a week, and developed widespread plaque psoriasis within weeks of starting …

Various cutaneous adverse reactions during treatment with IFNα were reported previously.
The most commonly reported adverse effect is injection-site reaction, occurring in …

Interferon therapy is the cornerstone of chronic hepatitis C treatment. Side effects of
interferon include possible triggering or exacerbation of immune diseases in consequence …

A 61-year-old man was observed to develop type 1 diabetes mellitus following a 3-month
treatment with recombinant α-2b peginterferon combined with ribavirin for chronic hepatitis …

Studies the cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and
ribavirin. Review of patients undergoing combination treatment with peginterferon alfa and …

Psoriasis and psoriatic arthritis are exacerbated by interferon alfa and other treatments for
hepatitis C virus infection. Immunosuppressants and hepatotoxic drugs are relatively …

Patients with psoriasis and chronic hepatitis C virus (HCV) infection are a therapeutic
challenge. Systemic psoriasis treatment with methotrexate and acitretin can be hepatotoxic …